| UniProt ID | CDS2_HUMAN | |
|---|---|---|
| UniProt AC | O95674 | |
| Protein Name | Phosphatidate cytidylyltransferase 2 | |
| Gene Name | CDS2 | |
| Organism | Homo sapiens (Human). | |
| Sequence Length | 445 | |
| Subcellular Localization |
Mitochondrion inner membrane Multi-pass membrane protein Matrix side . |
|
| Protein Description | Provides CDP-diacylglycerol, an important precursor for the synthesis of phosphatidylinositol, phosphatidylglycerol, and cardiolipin.. | |
| Protein Sequence | MTELRQRVAHEPVAPPEDKESESEAKVDGETASDSESRAESAPLPVSADDTPEVLNRALSNLSSRWKNWWVRGILTLAMIAFFFIIIYLGPMVLMIIVMCVQIKCFHEIITIGYNVYHSYDLPWFRTLSWYFLLCVNYFFYGETVTDYFFTLVQREEPLRILSKYHRFISFTLYLIGFCMFVLSLVKKHYRLQFYMFGWTHVTLLIVVTQSHLVIHNLFEGMIWFIVPISCVICNDIMAYMFGFFFGRTPLIKLSPKKTWEGFIGGFFATVVFGLLLSYVMSGYRCFVCPVEYNNDTNSFTVDCEPSDLFRLQEYNIPGVIQSVIGWKTVRMYPFQIHSIALSTFASLIGPFGGFFASGFKRAFKIKDFANTIPGHGGIMDRFDCQYLMATFVNVYIASFIRGPNPSKLIQQFLTLRPDQQLHIFNTLRSHLIDKGMLTSTTEDE | |
| Overview of Protein Modification Sites with Functional and Structural Information | ||
|
|
||
* ASA = Accessible Surface Area
| Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
|---|---|---|---|---|---|
| 2 | Phosphorylation | ------MTELRQRVA ------CCHHHHHHH | 43.67 | 26074081 | |
| 19 | Ubiquitination | PVAPPEDKESESEAK CCCCCCCCCCCCCCC | 62.57 | 33845483 | |
| 21 | Phosphorylation | APPEDKESESEAKVD CCCCCCCCCCCCCCC | 52.76 | 29255136 | |
| 23 | Phosphorylation | PEDKESESEAKVDGE CCCCCCCCCCCCCCC | 52.73 | 29255136 | |
| 31 | Phosphorylation | EAKVDGETASDSESR CCCCCCCCCCCCCCH | 36.67 | 29255136 | |
| 33 | Phosphorylation | KVDGETASDSESRAE CCCCCCCCCCCCHHH | 49.44 | 29255136 | |
| 35 | Phosphorylation | DGETASDSESRAESA CCCCCCCCCCHHHHC | 34.67 | 25159151 | |
| 37 | Phosphorylation | ETASDSESRAESAPL CCCCCCCCHHHHCCC | 40.52 | 23927012 | |
| 41 | Phosphorylation | DSESRAESAPLPVSA CCCCHHHHCCCCCCC | 33.91 | 30278072 | |
| 47 | Phosphorylation | ESAPLPVSADDTPEV HHCCCCCCCCCCHHH | 24.84 | 30266825 | |
| 51 | Phosphorylation | LPVSADDTPEVLNRA CCCCCCCCHHHHHHH | 23.15 | 30266825 | |
| 60 | Phosphorylation | EVLNRALSNLSSRWK HHHHHHHHCHHHHHH | 34.44 | 28270605 | |
| 63 | Phosphorylation | NRALSNLSSRWKNWW HHHHHCHHHHHHHHH | 23.31 | 28270605 | |
| 175 | Ubiquitination | FISFTLYLIGFCMFV HHHHHHHHHHHHHHH | 3.29 | 22817900 | |
| 179 | Ubiquitination | TLYLIGFCMFVLSLV HHHHHHHHHHHHHHH | 1.42 | 22817900 | |
| 180 | Ubiquitination | LYLIGFCMFVLSLVK HHHHHHHHHHHHHHH | 2.13 | 22817900 | |
| 184 | Phosphorylation | GFCMFVLSLVKKHYR HHHHHHHHHHHHHHH | 26.30 | 24719451 | |
| 198 (in isoform 2) | Ubiquitination | - | 16.31 | 21906983 | |
| 249 | Phosphorylation | FGFFFGRTPLIKLSP HHHHHCCCCCEECCC | 23.87 | 24719451 | |
| 250 | Ubiquitination | GFFFGRTPLIKLSPK HHHHCCCCCEECCCC | 30.63 | 22817900 | |
| 253 (in isoform 1) | Ubiquitination | - | 51.07 | 21890473 | |
| 253 | Ubiquitination | FGRTPLIKLSPKKTW HCCCCCEECCCCCCC | 51.07 | 21906983 | |
| 257 | Ubiquitination | PLIKLSPKKTWEGFI CCEECCCCCCCCCCH | 60.50 | 22817900 | |
| 258 | Ubiquitination | LIKLSPKKTWEGFIG CEECCCCCCCCCCHH | 63.35 | 22817900 | |
| 259 | Phosphorylation | IKLSPKKTWEGFIGG EECCCCCCCCCCHHH | 34.57 | - | |
| 287 | Ubiquitination | VMSGYRCFVCPVEYN HHHCCEEEEEEEEEE | 4.72 | 22817900 | |
| 289 | Ubiquitination | SGYRCFVCPVEYNND HCCEEEEEEEEEECC | 1.24 | 21890473 | |
| 328 | Ubiquitination | IQSVIGWKTVRMYPF HHHHHCCEEEECCCC | 31.74 | 22817900 | |
| 328 (in isoform 1) | Ubiquitination | - | 31.74 | 21890473 | |
| 357 | Ubiquitination | GPFGGFFASGFKRAF CCCCHHHHHCHHHHE | 13.39 | 22817900 | |
| 365 | Ubiquitination | SGFKRAFKIKDFANT HCHHHHEEHHHHHHC | 48.11 | 22817900 | |
| 367 (in isoform 1) | Ubiquitination | - | 47.59 | 21890473 | |
| 367 | Ubiquitination | FKRAFKIKDFANTIP HHHHEEHHHHHHCCC | 47.59 | 21890473 | |
| 391 | Phosphorylation | DCQYLMATFVNVYIA HHHHHHHHHHHHHHH | 17.72 | 22617229 | |
| 435 | 2-Hydroxyisobutyrylation | LRSHLIDKGMLTSTT HHHHHHHCCCCCCCC | 38.95 | - | |
| 435 (in isoform 1) | Ubiquitination | - | 38.95 | 21890473 | |
| 435 | Ubiquitination | LRSHLIDKGMLTSTT HHHHHHHCCCCCCCC | 38.95 | 22817900 | |
| 439 | Phosphorylation | LIDKGMLTSTTEDE- HHHCCCCCCCCCCC- | 18.35 | 21406692 | |
| 440 | Phosphorylation | IDKGMLTSTTEDE-- HHCCCCCCCCCCC-- | 29.39 | 21406692 | |
| 441 | Phosphorylation | DKGMLTSTTEDE--- HCCCCCCCCCCC--- | 29.03 | 21406692 | |
| 442 | Phosphorylation | KGMLTSTTEDE---- CCCCCCCCCCC---- | 41.00 | 21406692 |
| Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
|---|---|---|---|---|---|---|
Oops, there are no upstream regulatory protein records of CDS2_HUMAN !! | ||||||
| Modified Location | Modified Residue | Modification | Function | Reference | ||
|---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of CDS2_HUMAN !! | ||||||
* Distance = the distance between SAP position and PTM sites.
| Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
|---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of CDS2_HUMAN !! | ||||||
| Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
|---|---|---|---|---|
| TS101_HUMAN | TSG101 | physical | 21988832 |
| Kegg Disease | ||||||
|---|---|---|---|---|---|---|
| There are no disease associations of PTM sites. | ||||||
| OMIM Disease | ||||||
| There are no disease associations of PTM sites. | ||||||
| Kegg Drug | ||||||
| There are no disease associations of PTM sites. | ||||||
| DrugBank | ||||||
| There are no disease associations of PTM sites. | ||||||
loading...
| Phosphorylation | |
| Reference | PubMed |
| "Quantitative phosphoproteomic analysis of T cell receptor signalingreveals system-wide modulation of protein-protein interactions."; Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,Rodionov V., Han D.K.; Sci. Signal. 2:RA46-RA46(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37, AND MASSSPECTROMETRY. | |
| "Large-scale proteomics analysis of the human kinome."; Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,Mann M., Daub H.; Mol. Cell. Proteomics 8:1751-1764(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37, AND MASSSPECTROMETRY. | |
| "Large-scale phosphoproteome analysis of human liver tissue byenrichment and fractionation of phosphopeptides with strong anionexchange chromatography."; Han G., Ye M., Zhou H., Jiang X., Feng S., Jiang X., Tian R., Wan D.,Zou H., Gu J.; Proteomics 8:1346-1361(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-23 AND SER-33, AND MASSSPECTROMETRY. | |
| "Kinase-selective enrichment enables quantitative phosphoproteomics ofthe kinome across the cell cycle."; Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,Greff Z., Keri G., Stemmann O., Mann M.; Mol. Cell 31:438-448(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-21; SER-33 AND SER-37,AND MASS SPECTROMETRY. | |
| "Phosphoproteome of resting human platelets."; Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,Schuetz C., Walter U., Gambaryan S., Sickmann A.; J. Proteome Res. 7:526-534(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-33, AND MASSSPECTROMETRY. | |
| "Global, in vivo, and site-specific phosphorylation dynamics insignaling networks."; Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,Mann M.; Cell 127:635-648(2006). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-21, AND MASSSPECTROMETRY. | |